Clinical trials: Estrogen Activity
Metastatic Breast Cancer, Estrogen-receptor-positive Breast Cancer
The FEMA Study: Feasibility of Exercise in Patients With Metastatic Breast Cancer and Adiposity
The goal of this clinical trial is to test a physical activity program in patients with metastatic breast cancer and overweight receiving endocrine-based treatment.
- Conditions
- Metastatic Breast Cancer, Estrogen-receptor-positive Breast Cancer, Adiposity
- Trial name
- NCT06343987
- Testing
- Physical Activity
- Where
- Denmark
- Volunteers
- 21 people
- Sponsor
- Aarhus University Hospital
Breast Cancer
A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer
This is a multicenter, open label, Phase 1b study in patients with mBC. This study will have a dose escalation to identify the maximum tolerated dose (MTD) of the combination of gedatolisib plus palbociclib/fulvestrant and…
- Trial name
- NCT02684032
- Testing
- Gedatolisib, Palbociclib, Letrozole
- Where
- 41 sites in United States
- Volunteers
- 141 people
- Sponsor
- Celcuity Inc
Infant Formula, Estrogen Activity
Study of Infant Diets on Estrogen Activity and Development
This study, conducted at the University of Pennsylvania s Newborn Nursery, the Children s Hospital of Philadelphia, and the Exton Specialty Care Center, will examine how different infant diets may affect estrogen activity in…
- Trial name
- NCT00340665
- Where
- 2 sites in United States
- Volunteers
- 239 people
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Anorexia in Adolescence
Effect of Aerobic Exercises and Nutrition In Adolescent Girls With Anorexia
Randomized control study used to identify the effect of aerobic exercises on the activity of daily living and estradiol serum level in young girls with anorexia
- Trial name
- NCT05057000
- Testing
- aerobic exercises + Diet, diet proram
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Badr University
Activity of Lupus Nepheritis
Role of Estrogen in the Flarring up of Lupus Nepheritis
Role of estrogen in the flarring up of lupus nepheritis
- Trial name
- NCT04468438
- Testing
- serum estrogen and urinary albumin creatinine ratio
- Volunteers
- 100 people
- Sponsor
- Assiut University
Breast Cancer
A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
This clinical trial is evaluating AC682 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: 1.
- Trial name
- NCT05489679
- Testing
- AC682
- Where
- 3 sites in China
- Volunteers
- 6 people
- Sponsor
- Accutar Biotechnology Inc
Endometriosis
Effect of Mediterranean Diet and Physical Activity in Patients With Endometriosis
The main aim of this study is to evaluate whether a dietary recommendation based on the Mediterranean diet's principles associated with a regular aerobic physical activity, according to the "7 minutes workout", may improve pain…
- Trial name
- PHAMEDENDO (NCT03994432)
- Testing
- intervention group
- Where
- Italy
- Volunteers
- 140 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Women's Health
Isolated and Associated Effects of Physical Exercise and Estrogen Therapy on Climactercs Women
This study will investigate the isolated and the associated effect of estrogen therapy and physical exercise in the function, regulation and cardiovascular risk markers of 60 postmenopausal women, (45 - 60 years old).
- Trial name
- TRH01/989-7 (NCT01120665)
- Testing
- Estradiol valerate, Aerobic training, Control
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Perimenopause
Hemodynamics After Resistance Training
Women's blood vessel health gets worse after menopause, or "the change of life". Some women exercise less during menopause. Exercise can improve blood vessel health.
- Trial name
- HeART (NCT07022340)
- Testing
- Resistance Training Intervention
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Michigan
Periodontal Diseases, Periodontal Pocket
Predictors of Periodontal Outcomes Post-sanative Therapy
Periodontal disease is a chronic inflammatory disease of the tissues surrounding the teeth and is one of the leading causes of tooth loss.
- Trial name
- NCT04639661
- Where
- 2 sites in Canada
- Volunteers
- 12 people
- Sponsor
- Brock University
Postmenopause, Hypertension
Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension
The main purpose of this study is to compare the effects of treatment of two different formulations of Angeliq® and Prempro on blood pressure in post-menopausal women with prehypertension.
- Conditions
- Postmenopause, Hypertension, Pre-Hypertension
- Trial name
- NCT00420342
- Testing
- Drospirenone/17ß-estradiol (Angeliq, BAY86-4891), SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)
- Where
- 9 sites in United States
- Volunteers
- 92 people
- Sponsor
- Bayer
HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC)
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tumors with CCNE1…
- Conditions
- HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
- Trial name
- NCT07029399
- Testing
- NKT5097 CDK2/CDK4 dual degrader, Fulvestrant, Letrozole
- Where
- 18 sites in United States
- Volunteers
- 361 people
- Sponsor
- NiKang Therapeutics, Inc.
Breast Cancer
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
This is a first-in-human, Phase Ia/Ib, dose-escalation and expansion study evaluating the safety, pharmacokinetics, and activity of GDC-0587 (cyclin-dependent kinase-4 [CDK4] inhibitor) as a monotherapy and in combination with…
- Trial name
- NCT07214662
- Testing
- GDC-0587, Giredestrant, Omeprazole
- Where
- 4 sites in United States, Taiwan
- Volunteers
- 3 people
- Sponsor
- Genentech, Inc.
Women With ER Positive Breast Cancer Taking (AI) w Joint Discomfort and Stiffness
The Effect of an Exercise Program in Breast Cancer Patients With Joint Pain While Taking Aromatase Inhibitors.
The objective of this study is to determine if patients taking aromatase inhibitors (AI), who are experiencing joint discomfort and stiffness, would have reduction in this discomfort and stiffness by participating in a directed…
- Trial name
- NCT02057536
- Testing
- Arm A Directed exercise program, Observation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Christiana Care Health Services
Osteoporosis
Bone Estrogen Strength Training
We started the Bone, Estrogen, Strength Training (BEST) study in the fall of 1995 at the University of Arizona, Tucson, Arizona. The BEST study is the largest of its kind.
- Trial name
- NCT00000399
- Testing
- Hormone replacement therapy, Strength training
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Breast Cancer
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
The purpose of this study is to assess the safety of GDC-4198 alone and in combination with giredestrant and also the efficacy of GDC-4198 + giredestrant versus abemaciclib + giredestrant in participants with locally advanced or…
- Trial name
- MoonROSE (NCT07100106)
- Testing
- GDC-4198, Giredestrant, Abemaciclib
- Where
- 77 sites in United States, Australia and 8 more
- Volunteers
- 285 people
- Sponsor
- Genentech, Inc.
Breast Cancer, Solid Tumors
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07220060 and PF-07104091) in people with breast cancer. This clinical study consists of 2 parts (part 1 and part 2).
- Trial name
- NCT05262400
- Testing
- PF-07220060 + PF-07104091 combination dose escalation, PF-07104091 + PF-07220060 + fulvestrant dose expansion, PF-07104091 + PF-07220060 + letrozole dose expansion
- Where
- 44 sites in United States, Argentina and 7 more
- Volunteers
- 235 people
- Sponsor
- Pfizer
Estrogen Receptor-Positive, HER2-Negative
ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)
For patients with ER-positive, HER2-negative breast cancer, blockage of the ER pathway has been proven to be an effective anticancer approach. These patients showed good response to endocrine therapy.
- Conditions
- Estrogen Receptor-Positive, HER2-Negative, Locally Advanced Breast Cancer, Metastatic Breast Cancer
- Trial name
- ENZENO (NCT04669587)
- Testing
- ZB716, Palbociclib
- Where
- 8 sites in United States, South Korea
- Volunteers
- 106 people
- Sponsor
- EnhancedBio USA Inc.
Contraception, Birth Control
International Active Surveillance Study: Native Estrogen Estetrol (E4) Safety Study
Multinational, comparative, prospective, active surveillance study that follows two cohorts. The primary objective of the study is to characterize and compare the risks of E4/Drospirenone (DRSP) with levonorgestrel-containing…
- Trial name
- INAS-NEES (NCT06028555)
- Where
- Germany
- Volunteers
- 101,000 people, healthy volunteers welcome
- Sponsor
- Center for Epidemiology and Health Research, Germany
Carcinoma, Ductal, Breast, Breast Cancer Female
G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer
This is a study to investigate the potential clinical benefit of G1T48 as an oral selective estrogen receptor degrader (SERD) alone and in combination with palbociclib, a cyclin dependent kinase 4/6 (CDK 4/6) inhibitor, in…
- Conditions
- Carcinoma, Ductal, Breast, Breast Cancer Female, Breast Neoplasm, Breast Cancer
- Trial name
- NCT03455270
- Testing
- G1T48, Palbociclib
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 107 people
- Sponsor
- G1 Therapeutics, Inc.